553 related articles for article (PubMed ID: 15793224)
1. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
2. Role of pegylated liposomal doxorubicin in ovarian cancer.
Thigpen JT; Aghajanian CA; Alberts DS; Campos SM; Gordon AN; Markman M; McMeekin DS; Monk BJ; Rose PG
Gynecol Oncol; 2005 Jan; 96(1):10-8. PubMed ID: 15589573
[TBL] [Abstract][Full Text] [Related]
3. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
6. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
7. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME; Curiel T; Gómez JG; Jorge M
Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?
Lorusso D; Naldini A; Testa A; D'Agostino G; Scambia G; Ferrandina G
Oncology; 2004; 67(3-4):243-9. PubMed ID: 15557785
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
Gordon AN; Tonda M; Sun S; Rackoff W;
Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
[TBL] [Abstract][Full Text] [Related]
11. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
[TBL] [Abstract][Full Text] [Related]
14. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.
Campos SM; Penson RT; Mays AR; Berkowitz RS; Fuller AF; Goodman A; Matulonis UA; Muzikansky A; Seiden MV
Gynecol Oncol; 2001 May; 81(2):206-12. PubMed ID: 11330951
[TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
[TBL] [Abstract][Full Text] [Related]
16. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer.
Nicoletto MO; Falci C; Pianalto D; Artioli G; Azzoni P; De Masi G; Ferrazzi E; Perin A; Donach M; Zoli W
Gynecol Oncol; 2006 Feb; 100(2):318-23. PubMed ID: 16239023
[TBL] [Abstract][Full Text] [Related]
18. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]